A clinical trial of eye drop formulation of AKB-9778 to treat primary open angle glaucoma

Trial Profile

A clinical trial of eye drop formulation of AKB-9778 to treat primary open angle glaucoma

Planning
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs AKB 9778 (Primary)
  • Indications Open-angle glaucoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Mar 2018 New trial record
    • 13 Mar 2018 According to an Aerpio Pharmaceuticals media release, company expects to begin this trial within 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top